• 1
    Osoba D. The quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual Life Res 1992;1:2118.
  • 2
    Osoba D. Guidelines for measuring health-related quality of life in clinical trials. In: StaquetMJ, HaysRD, FayersPM, eds. Quality of Life Assessment in Clinical Trials. Oxford: Oxford University Press, 1998.
  • 3
    Osoba D. Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. Cancer Treat Rev 1996;22(Suppl. A):6973.
  • 4
    Fayers P, Aaronson N, Bjordal K, Sullivan M. EORTC QLQ-C30 Scoring Manual. Brussels, Belgium: EORTC Study Group on Quality of Life, 1995.
  • 5
    Sadura A, Pater J, Osoba D, et al. Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst 1992;84:10236.
  • 6
    Osoba D, Dancey J, Zee B, et al. Health-related quality of life studies of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst Monogr 1996;20:10711.
  • 7
    Osoba D, Zee B. Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group. Stat Med 1998;17:60312.
  • 8
    Aaronson NK, Ahmedzai S, Bullinger M, et al. The EORTC core quality of life questionnaire: interim results of an international field study. In: OsobaD, ed. Effect of Cancer on Quality of Life. Boca Raton, FL: CRC Press, 1991.
  • 9
    Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-life assessment in cancer clinical trials. In: ScheurlenH, KayR, BaumM, eds. Cancer Clinical Trials: A Critical Appraisal. Recent Results in Cancer Research, Vol. III. Berlin: Springer-Verlag, 1988.
  • 10
    Osoba D. Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology. Cancer Treat Rev 1993;19:4351.
  • 11
    Chen D. Supplementary health-related quality of life assessment in cancer clinical trials: added value to standard HRQoL instruments? Master's Thesis, Queen's University, Kingston, Ontario, Canada; September 2005.
  • 12
    Osoba D, Zee B, Pater J, et al. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire QLQ-C30 in patients with breast, ovarian and lung cancer. Qual Life Res 1994;3:35364.
  • 13
    Fayers P, Aaronson N, Bjordal K, et al. EORTC Scoring Manual, 2nd edn. Brussels, Belgium: Quality of Life Unit, EORTC Data Centre, 1999.
  • 14
    Fayers PM, Aaronson N, Bjordal K, et al. EORTC QLQ-C30 Scoring Manual, 3rd edn. Brussels, Belgium: EORTC Quality of Life Group, 2001.
  • 15
    Osoba D, Zee B, Warr D, et al. Quality of life studies in chemotherapy-induced emesis. Oncology 1996;53(Suppl. 1):925.
  • 16
    Osoba D, Zee B, Warr D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 1997;5:30713.
  • 17
    Osoba D, Zee B, Pater J, et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997;15:11623.
  • 18
    Pater J, Slamet L, Zee B, et al. Inconsistency of prognostic factors for postchemotherapy nausea and vomiting. Support Care Cancer 1994;2:1616.
  • 19
    Pater J, Osoba D, Zee B, et al. Effects of altering the time of administration and the timeframe of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in large antiemetic trials. Qual Life Res 1998;7:2738.
  • 20
    Huisman SJ, Van Dam FSAM, Aaronson NK, Hanewold GJFP. On measuring complaints of cancer patients: some remarks on the time span of the question. In: AaronsonNK, BeckmanJ, eds. The Quality of Life of Cancer Patients. New York: Raven Press, 1987.
  • 21
    Pater JL, Zee B, Palmer M, et al. Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30. Support Care Cancer 1997;5:4104.
  • 22
    Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:297194.
  • 23
    Dancey J, Zee B, Osoba D, et al. Quality of life score: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 1997;6:1518.
  • 24
    Osoba D, Zee B, Sadura A, et al. Measurement of quality of life in an adjuvant trial of gamma interferon versus levamisole in malignant melanoma. In: SalmonSE, ed. Adjuvant Therapy of Cancer VII. Philadelphia: JB Lippincott Co., 1993: 4126.
  • 25
    Bezjak A, Tu D, Bacon M, et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 2004;22:4595603.
  • 26
    Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:302534.
  • 27
    Shepherd F, Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:12332.
  • 28
    Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:23008.
  • 29
    Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:44727.
  • 30
    Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 1993;85:113848.
  • 31
    Paul N, Pater J, Whitehead M, Sadura A. Methods of toxicity data collection: an evaluation of the relative effectiveness of the case report flow sheet, the patient symptom diary, and the quality of life questionnaire. Control Clin Trials 1991;12:648.
  • 32
    Savage C, Pater J, Tu D, Norris B. He said/she said: how much agreement is there on symptoms between common toxicity criteria and quality of life? Proc Am Soc Clin Oncol 2002;21:386a (abstract 1540).
  • 33
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:40715.
  • 34
    Juniper ED, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:817.
  • 35
    Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life-scores. J Clin Oncol 1998;16:13944.
  • 36
    Ehrich EW, Davies GM, Watson DJ, et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000;27:263541.
  • 37
    King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:55567.
  • 38
    Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:28595.
  • 39
    Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:58292.
  • 40
    Farivar SS, Kiu H, Hays RD. Another look at the half standard deviation estimate of the minimally important difference in health-related quality of life scores. Expert Rev Pharmacoeconomics Outcomes Res 2004;4:5219.
  • 41
    Osoba D, Northfelt DW, Budd DW, Himmelberger D. Effect of treatment on health-related quality of life in AIDS-related Kaposi's sarcoma: a randomized trial of pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine. Cancer Invest 2001;19:57380.
  • 42
    Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:165463.
  • 43
    Osoba D. A taxonomy of the uses of health-related quality of life (HRQL) instruments in cancer care and the clinical meaningfulness of the results. Med Care 2002;40(Suppl.):III318.
  • 44
    Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20:310613.
  • 45
    Osoba D, Brada M, Yung WKA, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000;36:178895.
  • 46
    Osoba D, Brada M, Yung WKA, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000;18:148191.
  • 47
    Osoba D, Bezjak A, Brundage M, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:2807.
  • 48
    Liu J. Analysis of quality of life data from a clinical trial in patients with advanced breast cancer with a comparison of different statistical approaches. Master's Thesis, Queen's University, Kingston, Ontario, Canada; August 2002.
  • 49
    Zee B. Growth curve model analysis for quality of life data. Stat Med 1998;17:75766.
  • 50
    Fairclough D, Peterson H, Cella D, Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in clinical trials. Stat Med 1998;17:78196.
  • 51
    Fayers P, Machin D. Quality of Life: Assessment, Analysis and Interpretation. Chichester: John Wiley & Sons, 2000.